Theravance Biopharma, Inc. – NASDAQ:TBPH
Theravance Biopharma stock price today
$13.45
+3.85
+40.25%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 5 hours
Theravance Biopharma stock price monthly change
+2.35%
month
Theravance Biopharma stock price quarterly change
+2.35%
quarter
Theravance Biopharma stock price yearly change
-15.88%
year
Theravance Biopharma key metrics
Market Cap | 483.38M |
Enterprise value | 591.45M |
P/E | -9.18 |
EV/Sales | 11.51 |
EV/EBITDA | 0.60 |
Price/Sales | 16.31 |
Price/Book | 1.89 |
PEG ratio | -0.01 |
EPS | -0.86 |
Revenue | 61.51M |
EBITDA | -32.43M |
Income | -44.77M |
Revenue Q/Q | 39.22% |
Revenue Y/Y | 26.64% |
Profit margin | 1879.32% |
Oper. margin | -179.09% |
Gross margin | 21.52% |
EBIT margin | -179.09% |
EBITDA margin | -52.72% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeTheravance Biopharma stock price history
Theravance Biopharma stock forecast
Theravance Biopharma financial statements
Average Price Target
$12.5
Potential downside: -7.06%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 13.74M | -15.64M | -113.79% |
|---|---|---|---|
| Sep 2023 | 15.69M | -8.95M | -57.03% |
| Dec 2023 | 17.56M | -8.51M | -48.45% |
| Mar 2024 | 14.50M | -11.66M | -80.42% |
| Jun 2023 | 446630000 | 166.46M | 37.27% |
|---|---|---|---|
| Sep 2023 | 413590000 | 167.46M | 40.49% |
| Dec 2023 | 381999000 | 169.00M | 44.24% |
| Mar 2024 | 371307000 | 166.43M | 44.83% |
| Jun 2023 | -12.43M | 11.04M | -80.68M |
|---|---|---|---|
| Sep 2023 | -2.48M | -21K | -31.40M |
| Dec 2023 | -854K | -677K | -30.60M |
| Mar 2024 | -1.02M | 17.02M | -1.71M |
Theravance Biopharma alternative data
| Aug 2023 | 111 |
|---|---|
| Sep 2023 | 111 |
| Oct 2023 | 111 |
| Nov 2023 | 111 |
| Dec 2023 | 111 |
| Jan 2024 | 111 |
| Feb 2024 | 111 |
| Mar 2024 | 99 |
| Apr 2024 | 99 |
| May 2024 | 99 |
| Jun 2024 | 99 |
| Jul 2024 | 99 |
Theravance Biopharma other data
52.62%
-29.52%
of TBPH is owned by hedge funds
70
-47
38.72M
-23.30M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Feb 2024 | 0 | 1254 |
| May 2024 | 1499124 | 0 |
| Jul 2024 | 0 | 4000 |
| Nov 2024 | 0 | 4000 |
| Quarter | Transcript |
|---|---|
| Q1 2024 13 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 26 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 7 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 7 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Rick E. Winningham M.B.A. (1960) Chairman & Chief Executive Officer | $1,600,000 |
| Mr. Andrew Asa Hindman (1973) Senior Vice President & Chief Financial Officer | $822,810 |
Week In Review: Legend Partners DLL3 CAR-T Candidate With Novartis In $1.2 Billion Deal
Innoviva: A Lot Of Moving Parts
Theravance: Positive Findings Boost Ampreloxetine Development
Theravance Biopharma: YUPELRI Numbers Don't Substantiate 9x Forward Sales, Rate Hold
Theravance Biopharma: Activist Pressure Might Lead To Substantial Capital Return
Arena Pharmaceuticals: A Speculative Buy To Play The Upcoming Etrasimod's Data-Readout
20 Short Ideas With Super-Weak Momentum
-
What's the price of Theravance Biopharma stock today?
One share of Theravance Biopharma stock can currently be purchased for approximately $13.45.
-
When is Theravance Biopharma's next earnings date?
Unfortunately, Theravance Biopharma's (TBPH) next earnings date is currently unknown.
-
Does Theravance Biopharma pay dividends?
No, Theravance Biopharma does not pay dividends.
-
How much money does Theravance Biopharma make?
Theravance Biopharma has a market capitalization of 483.38M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 11.84% to 57.42M US dollars.
-
What is Theravance Biopharma's stock symbol?
Theravance Biopharma, Inc. is traded on the NASDAQ under the ticker symbol "TBPH".
-
What is Theravance Biopharma's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Theravance Biopharma?
Shares of Theravance Biopharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Theravance Biopharma's key executives?
Theravance Biopharma's management team includes the following people:
- Mr. Rick E. Winningham M.B.A. Chairman & Chief Executive Officer(age: 65, pay: $1,600,000)
- Mr. Andrew Asa Hindman Senior Vice President & Chief Financial Officer(age: 52, pay: $822,810)
-
How many employees does Theravance Biopharma have?
As Jul 2024, Theravance Biopharma employs 99 workers.
-
When Theravance Biopharma went public?
Theravance Biopharma, Inc. is publicly traded company for more then 11 years since IPO on 16 May 2014.
-
What is Theravance Biopharma's official website?
The official website for Theravance Biopharma is theravance.com.
-
How can i contact Theravance Biopharma?
Theravance Biopharma can be reached via phone at +65 08086000.
-
What is Theravance Biopharma stock forecast & price target?
Based on 2 Wall Street analysts` predicted price targets for Theravance Biopharma in the last 12 months, the avarage price target is $12.5. The average price target represents a -7.06% change from the last price of $13.45.
Theravance Biopharma company profile:
Theravance Biopharma, Inc.
theravance.comExchange:
NASDAQ
Full time employees:
99
Industry:
Biotechnology
Sector:
Healthcare
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; Nezulcitinib, a lung-selective, nebulized JAK inhibitor, which is in Phase II clinical development for the potential treatment of hospitalized patients with acute lung injury caused by COVID-19; Inhaled ALK5i, a potential inhaled anti-fibrotic agent that is in Phase I for the treatment of idiopathic pulmonary fibrosis; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY for the treatment of COPD and asthma; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Viatris Inc., Janssen Biotech, Inc., Alfasigma S.p.A, and Takeda Pharmaceutical Company Limited. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.
Ugland House
George Town, KY1-1104
George Town, KY1-1104
CIK: 0001583107
ISIN: KYG8807B1068
CUSIP: G8807B106
